On December 8th, Suzhou Linaxin Biotechnology Co., Ltd. signed a cooperation agreement with Xinlimeida (Suzhou) Medical Co., Ltd. (hereinafter referred to as "Xinlimeida Medical").

Xinlimeida (Suzhou) Medical Co., Ltd. is an enterprise specializing in medical devices and medical services. Through this cooperation, both parties had sufficient exchanges on important matters such as the construction and benign operation of a new early screening system for colorectal cancer. From screening education and training to early screening popularization, both parties will comprehensively integrate resources based on their own advantages. Xinlimeida Medical will vigorously promote the home type fecal occult blood testing product (Changlecin) under Linaxin Biotechnology ™） The utilization rate among early screening users for colorectal cancer benefits more early colorectal cancer patients.

Changle Xin ™ It is a colorectal cancer early screening product based on colloidal gold immunochromatography technology, which has the advantages of being at home, painless and non-invasive, easy to operate, and easy to judge. Compared to routine clinical stool examinations, Changle Xin ™ Can provide customers with a better testing experience. Meanwhile, Changle Xin ™ It has high sensitivity to colorectal cancer and early precancerous lesions, making it a high-quality health management product.

Screen a sample early!

Save a life!

Benefit a family!

Improve the health level of the people!